GPT and anemia: In the interim analysis of the phase III eXalt3 study, rash (67.8%), increased AST (37.8%), increased ALT (48.3%), pruritus (26.6%), nausea (22.4%), constipation (20.3%), edema (21.0%), anemia (14.0%), vomiting (11.9%), increased ALP (13.3%), increased blood creatinine (14.0%), increased γ-GTP (13.3%), and anorexia (11.2%) were reported.